Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1160/TH13-01-0042 http://scihub22266oqcxt.onion/10.1160/TH13-01-0042 C4505726!4505726!24136071     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Thromb+Haemost 2014 ; 111 (1): 88-93 Nephropedia Template TP {{tp|p=24136071|t=2014. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients |pdf=|usr=}}{{24136071}} gab.com Text Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients JO: Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=24136071 #FOAvip Background: Obesity increases the risk for venous thromboembolism (VTE), but whether high-dose thromboprophylaxis is safe and effective in morbidly obese inpatients is unknown. Objective: To quantify the efficacy and safety of high-dose thromboprophylaxis with heparin or enoxaparin in inpatients with weight >?100 kilograms (kg) within the BJC HealthCare system. Patients/Methods: In a retrospective cohort study, we analyzed 9241 inpatients with weight >?100 kg discharged from three hospitals in the BJC HealthCare system from 2010 through 2012. We compared the incidence of VTE in patients who received high-dose thromboprophylaxis (heparin 7500 units three times daily or enoxaparin 40 milligrams (mg) twice daily) to those who received standard doses (heparin 5000 units two or three times daily or enoxaparin 40 mg once daily). The primary efficacy outcome was hospital-acquired VTE identified by International Classification of Diseases (ICD)-9 diagnosis codes. The primary safety outcome was bleeding events identified by ICD-9 codes. Results: Among the 3928 morbidly obese inpatients (weight >?100kg and body mass index (BMI) ??40 kg/m2), high-dose thromboprophylaxis approximately halved the odds of symptomatic VTE (odds ratio (OR) 0.52, 95% CI 0.27-1.00; p-value (p) = 0.050). The rate of VTE was 1.48% (35/2369) in these morbidly obese inpatients who received standard doses of thromboprophylaxis, compared to 0.77% (12/1559) in those who received high doses. High-dose thromboprophylaxis did not increase bleeding (OR 0.84, 95% CI 0.66-1.07, p = 0.15). Independent predictors of VTE include surgery, male, cancer, and BMI. Conclusions: High-dose thromboprophylaxis nearly halves the rate of VTE in morbidly obese inpatients. Twit Text FOAVip Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients ????Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=24136071 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24136071 #FOAvip English Wikipedia <ref>{{Cite pmid|24136071}}</ref> Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients #MMPMID24136071 Wang TF; Milligan PE; Wong CA; Deal EN; Thoelke MS; Gage BF Thromb Haemost 2014[Jan]; 111 (1): 88-93 PMID24136071show ga Background: Obesity increases the risk for venous thromboembolism (VTE), but whether high-dose thromboprophylaxis is safe and effective in morbidly obese inpatients is unknown. Objective: To quantify the efficacy and safety of high-dose thromboprophylaxis with heparin or enoxaparin in inpatients with weight >?100 kilograms (kg) within the BJC HealthCare system. Patients/Methods: In a retrospective cohort study, we analyzed 9241 inpatients with weight >?100 kg discharged from three hospitals in the BJC HealthCare system from 2010 through 2012. We compared the incidence of VTE in patients who received high-dose thromboprophylaxis (heparin 7500 units three times daily or enoxaparin 40 milligrams (mg) twice daily) to those who received standard doses (heparin 5000 units two or three times daily or enoxaparin 40 mg once daily). The primary efficacy outcome was hospital-acquired VTE identified by International Classification of Diseases (ICD)-9 diagnosis codes. The primary safety outcome was bleeding events identified by ICD-9 codes. Results: Among the 3928 morbidly obese inpatients (weight >?100kg and body mass index (BMI) ??40 kg/m2), high-dose thromboprophylaxis approximately halved the odds of symptomatic VTE (odds ratio (OR) 0.52, 95% CI 0.27-1.00; p-value (p) = 0.050). The rate of VTE was 1.48% (35/2369) in these morbidly obese inpatients who received standard doses of thromboprophylaxis, compared to 0.77% (12/1559) in those who received high doses. High-dose thromboprophylaxis did not increase bleeding (OR 0.84, 95% CI 0.66-1.07, p = 0.15). Independent predictors of VTE include surgery, male, cancer, and BMI. Conclusions: High-dose thromboprophylaxis nearly halves the rate of VTE in morbidly obese inpatients. äEfficacy and safety of high-dose thromboprophylaxis in morbidly obese (epmc).pdf DeepDyve Pubget Overpricing